The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.
Enliven Therapeutics believes its candidate ELVN-001 could become a second-line therapy in chronic myeloid leukemia (CML) and eventually challenge Novartis’s Scemblix in first-line use, and has just raised $230m to fund its development.
The share offer fundraising on June 16 followed strong Phase I results for ELVN-001 presented at the European Hematology Association...
The France-headquartered firm’s eye drop has demonstrated efficacy in a second pivotal trial.
The company took a prophylactic C3 inhibitor out of the immunomodulatory regimen used in its Phase II study of RP-A501, lowered the dose and adjusted its use of eculizumab.
All eyes on chronic urticaria after eosinophilic esophagitis disappointment.
An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger
All eyes on chronic urticaria after eosinophilic esophagitis disappointment.
An updated abstract from the World Conference on Lung Cancer has given analysts confidence in BioNTech’s VEGF-A/PD-L1 bispecific challenger
The total value of deals for GLP-1-associated assets so far this year is already double that of the previous two years combined, with China-originated molecules accounting for a substantial majority. Scrip takes a look at some of the key factors behind this activity.
